UY31532A1 - Inhibidores de cinesina como productos terapéuticos para el cancer - Google Patents

Inhibidores de cinesina como productos terapéuticos para el cancer

Info

Publication number
UY31532A1
UY31532A1 UY31532A UY31532A UY31532A1 UY 31532 A1 UY31532 A1 UY 31532A1 UY 31532 A UY31532 A UY 31532A UY 31532 A UY31532 A UY 31532A UY 31532 A1 UY31532 A1 UY 31532A1
Authority
UY
Uruguay
Prior art keywords
cancers
inhibitors
compounds
cinesine
cancer
Prior art date
Application number
UY31532A
Other languages
English (en)
Spanish (es)
Inventor
Annette Olga Walter
Michel Faure
David Duhl
Paul A Renhowe
Paul A Barsanti
Abrams Tinya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31532(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31532A1 publication Critical patent/UY31532A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY31532A 2007-12-14 2008-12-15 Inhibidores de cinesina como productos terapéuticos para el cancer UY31532A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
UY31532A1 true UY31532A1 (es) 2009-08-03

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31532A UY31532A1 (es) 2007-12-14 2008-12-15 Inhibidores de cinesina como productos terapéuticos para el cancer

Country Status (30)

Country Link
US (2) US8252832B2 (enExample)
EP (1) EP2229170B1 (enExample)
JP (1) JP5501976B2 (enExample)
KR (1) KR20100098394A (enExample)
CN (1) CN101939005B (enExample)
AR (1) AR069676A1 (enExample)
AU (1) AU2008337570B2 (enExample)
BR (1) BRPI0821248A2 (enExample)
CA (1) CA2708822A1 (enExample)
CL (1) CL2008003707A1 (enExample)
CO (1) CO6290651A2 (enExample)
CR (1) CR11412A (enExample)
DO (1) DOP2010000175A (enExample)
EA (1) EA018014B1 (enExample)
EC (1) ECSP10010248A (enExample)
ES (1) ES2459442T3 (enExample)
GE (1) GEP20125647B (enExample)
GT (1) GT201000172A (enExample)
IL (1) IL205831A0 (enExample)
MA (1) MA31872B1 (enExample)
MY (1) MY150214A (enExample)
NI (1) NI201000091A (enExample)
NZ (1) NZ585142A (enExample)
PA (1) PA8807801A1 (enExample)
PE (1) PE20091451A1 (enExample)
SM (1) SMP201000095B (enExample)
TN (1) TN2010000204A1 (enExample)
TW (1) TW200930704A (enExample)
UY (1) UY31532A1 (enExample)
WO (1) WO2009077448A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
WO2014151030A1 (en) * 2013-03-15 2014-09-25 Novartis Ag Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576221B2 (en) * 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
EP2106399A2 (en) 2007-01-05 2009-10-07 Novartis AG Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)

Also Published As

Publication number Publication date
IL205831A0 (en) 2010-11-30
NI201000091A (es) 2011-03-15
PA8807801A1 (es) 2009-07-23
WO2009077448A1 (en) 2009-06-25
JP5501976B2 (ja) 2014-05-28
US8664256B2 (en) 2014-03-04
ES2459442T3 (es) 2014-05-09
EP2229170A1 (en) 2010-09-22
MA31872B1 (fr) 2010-11-01
NZ585142A (en) 2012-03-30
SMP201000095B (it) 2011-09-09
CA2708822A1 (en) 2009-06-25
MY150214A (en) 2013-12-13
CL2008003707A1 (es) 2009-06-05
KR20100098394A (ko) 2010-09-06
GT201000172A (es) 2012-04-30
US8252832B2 (en) 2012-08-28
EA018014B1 (ru) 2013-04-30
CR11412A (es) 2010-06-30
AU2008337570B2 (en) 2012-04-05
JP2011506402A (ja) 2011-03-03
ECSP10010248A (es) 2010-07-30
DOP2010000175A (es) 2010-06-30
EP2229170B1 (en) 2014-01-22
GEP20125647B (en) 2012-09-25
CO6290651A2 (es) 2011-06-20
TW200930704A (en) 2009-07-16
US20090239922A1 (en) 2009-09-24
AU2008337570A1 (en) 2009-06-25
CN101939005B (zh) 2015-12-16
CN101939005A (zh) 2011-01-05
US20130012560A1 (en) 2013-01-10
EA201000900A1 (ru) 2011-02-28
AR069676A1 (es) 2010-02-10
SMAP201000095A (it) 2010-09-10
PE20091451A1 (es) 2009-10-19
BRPI0821248A2 (pt) 2015-06-16
TN2010000204A1 (en) 2011-11-11

Similar Documents

Publication Publication Date Title
UY31532A1 (es) Inhibidores de cinesina como productos terapéuticos para el cancer
MX2025000271A (es) Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
DOP2003000614A (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole
ECSP109965A (es) Imidazoles fusionados para el tratamiento del cancer
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
CO6710897A2 (es) Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
ECSP066362A (es) Inhibidores de quinesina mitótica.
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
CO2022019316A2 (es) Inhibidores alostéricos de egfr y métodos de uso de estos
CR7882A (es) Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas
AR059294A1 (es) Derivados de indazol-heteroarilo
CL2025000445A1 (es) Inhibidores de kif18a y usos de estos
MX2023014466A (es) Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
MX2025001164A (es) Inhibidores de calicreina plasmatica.
CU20100121A7 (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
WO2022236255A3 (en) Heterocyclic compounds as kinase inhibitors
GT200500219A (es) 4-(2,4-dicloro-5-metoxifenil)amino-6-metoxi-7([5-amino-sustituido)metil]-3-furil)-3-quinolincarbonitrilos comoinhibidores de quinasa.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171019